Treatment of a patient with HIV and metastatic melanoma with consecutive Ipilimumab and Nivolumab

Abstract

Recently new therapeutic agents were developed leading to a paradigm shift in melanoma treatment by the approval of checkpoint inhibitors and targeted therapies. However, in clinical trials HIV-infected melanoma patients have been excluded due to their condition and no randomized double-blind placebo-controlled studies have been published to evaluate the efficacy of these therapies in melanoma patients with concomitant HIV infection.

We report on a HIV-positive melanoma patient treated sequentially with ipilimumab and nivolumab whose CD4 count and virus replication have been monitored closely.

This article is protected by copyright. All rights reserved.

http://ift.tt/2tus4Tq